Merck discontinues development of possible COVID-19 vaccines following results
Published
Kenilworth-based Merck has announced the company is discontinuing development of its COVID-19 vaccine candidates, V590 and V591.
Full ArticlePublished
Kenilworth-based Merck has announced the company is discontinuing development of its COVID-19 vaccine candidates, V590 and V591.
Full ArticleWith its large population and fragile health systems, Africa has recorded more than three million Covid-19 cases, still less deadly..